The company reported $47.3 million in revenue and a gross margin expansion to 89% as it transitions to branded GLP-1 therapies, while reiterating expectations for a return to positive adjusted EBITDA in the second half of 2026.
The company reported $47.3 million in revenue and a gross margin expansion to 89% as it transitions to branded GLP-1 therapies, while reiterating expectations for a return to positive adjusted EBITDA in the second half of 2026.